Randomized trial reveals the design of a metabolic-stable peptide enhancing blood glucose control in diabetes and obesity, suggesting new therapeutic pathways.
Key Points
This work aims to design effective peptides that act as agonists for three hormone receptors to better control diabetes and obesity.
Utilized in silico mutagenesis for peptide design.
Modelled binding profiles through long molecular simulations.
Engineered peptides for metabolic stability and proteolytic resistance.
Peptides demonstrated a highly favorable effective binding enthalpy for GIP, GLP-1, and GCGR.
Targeted specificity for the three receptors was significantly improved compared to endogenous peptides.
Potential pathways for lower-dose oral formulations with reduced gastrointestinal side effects were identified.